IHE Fees and Costs — iShares U.S. Pharmaceuticals ETF
Data updated: 2026-08-24
The net expense ratio is 0.38%. There are no sales loads or redemption fees. In fiscal 2026 the fund paid $62K in broker commissions, 0.0087% of average net assets, and portfolio turnover was 24%.
IHE Fees and Expenses
Annual operating expenses and sales charges of IHE. Prospectus, as of March 31, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.38% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.00% |
| Gross expense ratio | 0.38% |
| Fee waiver | — |
| Net expense ratio | 0.38% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | No |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
IHE Costs Over Time
On $10,000 invested in IHE, assuming 5% a year before costs, total costs come to $246 over 5 years, cutting the return by 0.41% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.38%) | $40 | $125 | $219 |
| Trading costs (broker commissions) | $1 | $3 | $5 |
| Lost growth on money paid in costs | $0 | $6 | $22 |
| Total costs | $41 | $134 | $246 |
| Value after costs | $10,459 | $11,442 | $12,517 |
| Impact on return, per year | 0.41% | 0.41% | 0.41% |
IHE Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending March 31, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.0087%
- Total broker commissions: $62K
- Bought from dealers (principal trades, not a cost): $726.6M
- Portfolio turnover (prospectus): 24%
- Securities on loan, average value: $30.4M
- Net income from securities lending: $74K (0.010% of average net assets)
IHE Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Cantor Fitzgerald & Co. | $13K | 23.63% |
| Goldman Sachs & Co. LLC | $12K | 22.36% |
| BNP Paribas Securities Corp. | $6K | 10.76% |
| Cowen and Company, LLC | $6K | 10.12% |
| BofA Securities, Inc. | $5K | 8.63% |
| Morgan Stanley & Co. LLC | $4K | 7.17% |
| Jefferies LLC | $3K | 4.91% |
| UBS Securities LLC | $3K | 4.81% |
| Barclays Capital Inc. | $3K | 4.57% |
| Piper Sandler & Co. | $2K | 3.03% |
IHE Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| Citadel Securities LLC | $153.2M | 21.08% |
| Jane Street Capital, LLC | $100.5M | 13.83% |
| Citigroup Global Markets Inc. | $100.4M | 13.82% |
| RBC Capital Markets, LLC | $89.1M | 12.26% |
| Virtu Americas LLC | $82.4M | 11.34% |
| BofA Securities, Inc. | $57.3M | 7.88% |
| Goldman Sachs & Co. LLC | $48.9M | 6.73% |
| Morgan Stanley & Co. LLC | $34.0M | 4.68% |
| BNP Paribas Securities Corp. | $33.0M | 4.54% |
| J.P. Morgan Securities LLC | $27.9M | 3.83% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.